Bioavailability Challenge

Merck Millipore to invest in bioavailability

Merck Millipore to open new bioavailability lab in 2013

By Gareth Macdonald

The bioavailability market lacks a leader that can offer comprehensive solutions according to Merck Millipore, which has set its sights on filling the gap through investments and a new lab.

BE/BA, FDA, bioRASI, GDUFA

BE/BA sites must be logged with US FDA under GDUFA

By Gareth Macdonald

CROs conducting bioequivalence and bioavailability (BE/BA) studies for generics firms will have to log details of their sites with the US FDA under new ‘self-identification’ rules.